

Kallmann syndrome

The Kallmann syndrome (KS) combines hypogonadotropic hypogonadism (HH) with anosmia. This is a clinically and genetically heterogeneous disease. *KAL1*, encoding the extracellular glycoprotein anosmin-1, is responsible for the X chromosome-linked recessive form of the disease. Mutations in *FGFR1* or *FGF8*, encoding fibroblast growth factor receptor-1 and fibroblast growth factor-8, respectively, underlie an autosomal dominant form with incomplete penetrance. Finally, mutations in *PROKR2* and *PROK2*, encoding prokineticin receptor-2 and prokineticin-2, have been found in heterozygous, homozygous, and compound heterozygous states. These two genes are likely to be involved both in monogenic recessive and digenic/oligogenic KS transmission modes. Notably, mutations in any of the above-mentioned KS genes have been found in less than 30% of the KS patients, which indicates that other genes involved in the disease remain to be discovered.

In brief

- KS is a genetically heterogeneous developmental disease that most often manifests as absent spontaneous puberty combined with a defective sense of smell (hyposmia or anosmia).
- Some non-reproductive non-olfactory anomalies can also be present, depending on the genetic form of the disease.
- Disease prevalence has been roughly estimated at 1:8000 males and 1:40000 females, but might be underestimated especially in females.
- Main differential diagnoses are normosmic idiopathic hypogonadotropic hypogonadism and CHARGE syndrome.
- Different modes of KS transmission include X chromosome-linked recessive, autosomal recessive, autosomal dominant with incomplete penetrance, and most probably digenic/oligogenic inheritance.
- Mutations in any of the five known disease genes (*KAL1*, *FGFR1*, *FGF8*, *PROKR2*, *PROK2*) have been identified in a relatively small proportion (less than 30%) of the patients.
- As many as 30% of the mutations found in *FGFR1* might be *de novo* mutations, certainly a possibility to be considered before assessing recurrence risk of this genetic form in a family.
- Genetic testing strategy (Figure 1) is based on patient's gender, familial history (if any) and putative mode of disease inheritance, and the presence of additional clinical anomalies that may direct the geneticist towards a particular disease gene or occasionally a contiguous gene syndrome.
- Treatment of KS is that of the hypogonadism. There is currently no treatment for olfactory deficit. In both sexes, hormone replacement therapies are used to stimulate the development of secondary sexual characteristics at the time of puberty, and later to induce fertility.

Catherine Dodé^{*1} and Jean-Pierre Hardelin^{*2}

¹Inserm U567, Département de Génétique et Développement, Institut Cochin, Paris, France; ²Inserm U587, Département de Neurosciences, Institut Pasteur, Paris, France

European Journal of Human Genetics (2009) 17, 139–146;
doi:10.1038/ejhg.2008.206; published online 5 November 2008

Keywords: Kallmann syndrome; *KAL1*; *FGFR1*; *FGF8*; *PROKR2*; *PROK2*

*Correspondence: Dr C Dodé, Département de génétique et développement, Institut Cochin, 24 rue du Faubourg Saint Jacques, Paris 75014, France. Tel: +33 1 44 41 24 83; Fax: +33 1 58 41 15 80;
E-mail: catherine.dode@inserm.fr
or Dr J-P Hardelin, Inserm U587, Institut Pasteur, 25 rue du Dr Roux, Paris 75015, France. Tel: +33 1 45 68 88 91; Fax: +33 1 40 61 34 42;
E-mail: jean-pierre.hardelin@pasteur.fr

Received 29 May 2008; revised 8 September 2008; accepted 1 October 2008; published online 5 November 2008

Introduction

Maestre de San Juan was probably the first to report, in 1856, the association of the absence of olfactory structures in the brain and the presence of small testes in an individual.¹ The syndrome was identified as a clinical entity in 1944 by an American medical geneticist, Kallmann, who carried out a study on the occurrence of hypogonadism accompanied by anosmia in three affected families.² He showed the cosegregation of the anosmia and the hypogonadism in all the affected individuals, and therefore established that this syndrome can be hereditary. In the 1950s, the Swiss anatomist de Morsier further documented the disease by describing the underdevelopment or absence of the olfactory bulbs and tracts in several

male patients with hypogonadism.³ Some years later, the hypogonadism was ascribed to gonadotropin-releasing hormone (GnRH) deficiency.⁴

The prevalence of KS is still unknown. It has been roughly estimated at one out of 8000 in boys. In girls, the prevalence is thought to be five times lower, but is probably underestimated because some affected females only have mild hypogonadism (see below). Moreover, primary amenorrhea in females often remains unexplored.

Clinical overview

The Kallmann syndrome typically combines severe HH with a complete absence of the sense of smell (anosmia). The degree of the hypogonadism and that of the smell deficiency can, however, vary significantly, not only between unrelated patients, but also within affected families^{5,6} (and see pedigrees in references^{7–14}), even between monozygotic twins.^{15,16} In some families, both typical KS phenotypes and dissociated phenotypes with either hypogonadism or anosmia have been described.^{7,10,13,14,17} In addition, apparent reversal of the hypogonadism after discontinuation of hormonal treatment has been reported in a few KS patients.^{9,18,19} Finally, a variety of non-reproductive non-olfactory additional anomalies are present in only a fraction of KS patients. These disorders include involuntary upper limb mirror movements (bimanual synkinesis),^{17,20–22} abnormal eye movements,^{21,23} congenital ptosis,^{24,25} abnormal visual spatial attention,²⁶ hearing impairment,^{5,6,8,27–29} agenesis of the corpus callosum,^{7,13} unilateral (occasionally bilateral) renal agenesis,^{30–32} cleft lip or palate,^{5–7,33} agenesis of one or several teeth (hypodontia),^{7,24,33,34} obesity^{6,10} and other less documented anomalies (see reference³⁵ for review).

Differential diagnosis: normosmic idiopathic HH and CHARGE syndrome

Difficulties are encountered at both ends of KS phenotypic spectrum that is either in the absence of a conspicuous smell deficiency or when non-reproductive non-olfactory additional anomalies are present on top of a typical KS (see Figure 1).

Given the variable degree of hyposmia in KS, the distinction between KS and normosmic idiopathic HH (nIHH) is currently unclear, especially as HH patients do not always undergo detailed olfactory testing. There is genetic evidence, however, to suggest that nIHH and KS represent distinct nosological entities. Indeed, the genes encoding GnRH and kisspeptin receptors that are involved in nIHH^{37–39} do not seem to be required for the embryonic migration of neuroendocrine GnRH cells, the process likely to be defective in KS patients (see below). Large scale genetic testing of genuine nIHH cases for the presence of

mutations in KS genes should help to clarify this issue. The recent report of a family in which deleterious *GNRHR* and *FGFR1* missense mutations cosegregated in the nIHH individuals indicates, however, that the situation could be more complicated than anticipated.⁴⁰

CHARGE syndrome has an estimated birth incidence of 1 in 8500–12 000. The defining features that make the acronym are coloboma, heart anomalies, choanal atresia, retardation of growth and/or development, genital and ear anomalies. However, no single feature is universally present or sufficient for the diagnosis of CHARGE syndrome. Other frequently occurring features include characteristic face and hand dysmorphia, hypotonia, arhinencephaly, semicircular canal agenesis or hypoplasia, hearing impairment, urinary tract anomalies, orofacial clefting, dysphagia, and tracheo-oesophageal anomalies. New diagnostic criteria have been proposed in the past few years (see reference⁴¹). Moreover, it has been reported that most if not all CHARGE patients have both olfactory bulb aplasia or hypoplasia and HH,^{42,43} that is, the two KS defining features. Consequently, previously reported KS cases associated with congenital heart disease⁴⁴ or choanal atresia⁴⁵ could in fact represent unrecognised mild CHARGE cases.⁴⁶ CHARGE syndrome shares additional traits with the *KAL2* genetic form of KS (see below), including cleft lip or palate, present in 20–35% of *KAL2*^{7,11–13} and CHARGE⁴⁷ patients, external ear malformation, noted in virtually all CHARGE patients⁴⁷ and a few *KAL2* patients,⁴⁸ agenesis of the corpus callosum, reported in several CHARGE⁴⁷ and *KAL2* patients,^{7,13} and coloboma that is highly prevalent in CHARGE patients⁴⁷ and has been reported in at least one *KAL2* patient too.⁷ Most individuals with CHARGE syndrome are heterozygous for loss-of-function mutations in *CHD7* that encodes a chromodomain (chromatin organisation modifier domain) helicase DNA-binding protein.^{49,50} Because of the similarity between CHARGE and *KAL2* phenotypes, it is tempting to speculate that there are functional interactions between *CHD7* and the *FGFR1*-signalling pathway.

Diagnostic approaches

Most cases are diagnosed at the time of puberty because of the lack of sexual development, identified by small testes and absent virilisation in males or the lack of breast development and primary amenorrhea in females. KS is diagnosed when low serum gonadotropins and gonadal steroids are coupled with a compromised sense of smell. The latter should be ascertained by means of detailed questioning and olfactory screening tests,^{51–54} because it is rarely mentioned spontaneously. Magnetic resonance imaging (MRI) of the forebrain can be carried out to show the hypoplasia or aplasia of the olfactory bulbs and tracts⁵⁵ (Figure 2). MRI is also useful to exclude hypothalamic or




Figure 1 Genetic testing strategy for Kallmann syndrome. The strategy is based on patient's gender, familial history (if any) and putative mode of disease inheritance, and the presence of additional clinical anomalies that may direct the geneticist towards a particular disease gene or, occasionally, a contiguous gene syndrome at Xp22.3³⁶ or 8p11.2 p12.⁷ The search for *KALI* mutations is restricted to affected males, either isolated cases or patients with a familial history compatible with X-linked recessive mode of inheritance. Mutation screening of the known KS genes (*KALI*, *FGFR1*, *FGF8*, *PROKR2*, *PROK2*) leads to the identification of a mutation in less than one-third of the patients. Notably, as many as 30% of the mutations found in *FGFR1* might be *de novo* mutations, certainly a possibility to be considered before assessing recurrence risk of this genetic form in a family. The main differential diagnoses of KS are normosmic idiopathic hypogonadotropic hypogonadism and CHARGE syndrome.

pituitary lesions as the cause of HH.⁵⁶ The GnRH deficiency can be indirectly assessed by means of endocrinological tests (see reference⁵⁷).

Notably, KS may also be suspected as early as in infancy in boys, in the presence of cryptorchidism or a micropenis, combined with subnormal LH and FSH concentrations. Indeed, the postnatal surge in FSH, LH, and testosterone in the male infant as a consequence of the continued function of the fetal GnRH pulse generator provides a 6-month window of opportunity to establish the diagnosis of HH,⁵⁸ and alert the clinician to the possibility of its association with olfactory impairment. In this respect, the usefulness of forebrain MRI in diagnosing the disease in children too young to undergo meaningful testing of olfaction or of the hypothalamo-pituitary-gonadal axis should be emphasised,^{59,60} even though normal olfactory bulb images have been reported in a few KS patients.^{22,29}

Finally, the presence of non-reproductive non-olfactory additional disorders, including mirror movements, palate anomalies, renal agenesis (ultrasonography), hearing impairment (audiometric testing), and tooth agenesis, should be carefully searched in the patients and, whenever possible, their first-degree relatives, because such anomalies can direct the geneticist towards particular genetic forms of the disease (see below and Figure 1). In KS-affected families, the cleft palate or renal agenesis diagnosed by means of fetal ultrasonography may occasionally reveal the disease before birth.

The complex genetics of KS

Although most KS patients present as sporadic cases, many cases are clearly familial, with three modes of inheritance




Figure 2 Cranial magnetic resonance imaging (MRI) of the olfactory bulb region in a control man (a and b) and a man affected by Kallmann syndrome (c and d). (a and b) MRI T2-weighted sequence in coronal plane shows normal olfactory bulbs in the control individual (a, white arrows), and posterior to the olfactory bulbs, good differentiation of the rhinal sulci (b, white arrows) and olfactory tracts (b, white arrowheads). (c) MRI T2-weighted sequence in coronal plane shows very small olfactory bulbs in the KS patient (white arrows). On the right side, the rhinal sulcus (white arrowhead) is visible, with good differentiation between the right gyrus and orbital gyrus. On the left side, there is no rhinal sulcus (black arrowhead), and no differentiation between the right and orbital gyri. (d) MRI T1-weighted sequence in coronal plane, posterior to olfactory bulbs, confirms the presence of the rhinal sulcus on the right side (white arrow), with a relatively good differentiation between the right (white arrowhead) and orbital (black arrowhead) gyri, and the absence of the rhinal sulcus on the left side (black arrow).

being reported: X chromosome-linked recessive (OMIM no. 308700), autosomal dominant (OMIM no. 147950), and autosomal recessive (OMIM no. 244200) (<http://www.ncbi.nlm.nih.gov/omim/>). In the autosomal dominant form, incomplete penetrance has been emphasized.^{5,61}

Five causal genes have been identified to date, namely, by chronological order of discovery, *KAL1*,^{62–64} *FGFR1*,⁷ *PROKR2* and *PROK2*,¹⁰ and *FGF8*.⁶⁵ Various loss-of-function mutations in *KAL1*, encoding the extracellular matrix glycoprotein anosmin-1, and in *FGFR1* or *FGF8*, encoding fibroblast growth factor receptor-1 and fibroblast growth factor-8, underlie the X chromosome-linked form (KAL1) and an autosomal dominant form (KAL2) of KS, respectively (see Supplementary Tables S1, S2 and S3 for a list of the mutations). The KAL1 and KAL2 genetic forms account for roughly 8% and 10% of all KS cases, respectively. Mutations in *KAL1* are mainly nonsense mutations, frame-shift mutations, or large gene deletions, whereas the

majority of mutations in *FGFR1* (ie, approximately 70%) or *FGF8* (all six mutations reported so far) are missense mutations. Notably, as many as 30% of the *FGFR1* mutations found in the patients could be *de novo* mutations^{13,48,66} (C Dodé, unpublished results). Putative loss-of-function mutations in *PROKR2* or *PROK2*, encoding prokineticin receptor-2 and prokineticin-2, respectively, have been detected in approximately 9% of the KS patients (see Supplementary Table S4 for a list of the mutations). Most of these mutations are missense mutations, and many have also been found in apparently unaffected individuals, thus raising questions regarding their pathogenic role in the disease. Deleterious effects on prokineticin signalling, however, have subsequently been shown *in vitro* for nearly all the missense mutations.^{67,68} The finding, for given *PROKR2* and *PROK2* mutations, of both heterozygous and homozygous (or compound heterozygous) unrelated patients^{10,69} is quite remarkable, and argues in favour of a digenic or oligogenic mode of inheritance in heterozygous

patients. To date, digenic inheritance of KS has been shown in three such patients, who had monoallelic missense mutations both in *PROKR2* and *PROK2*,⁶⁷ *FGFR1* (C Dodé, unpublished), or *KAL1*.¹⁰ It is tempting to speculate that the latter patient bears a hypomorphic *KAL1* allele encoding a protein variant that would still retain some biological activity, whereas the vast majority of the *KAL1* mutations reported so far lead to null alleles that are apparently sufficient to produce the abnormal phenotype in males. Other patients carrying heterozygous mutations in *PROKR2*, *PROK2*, or hypomorphic mutations in *KAL1* are expected to carry additional mutations in other, as yet unknown, KS genes. Indeed, mutations in the five known genes together account for less than 30% of KS cases, indicating that other genes responsible for the disease remain to be discovered, some of which might also be involved in FGF signalling or prokineticin signalling. Notably, recent evidence indicates that oligogenic mode of inheritance may also apply to patients carrying mutations in *FGFR1* or *FGF8*. Three patients carrying missense mutations in *FGFR1* have indeed been found to also have a monoallelic or a biallelic mutation in *FGF8*,⁶⁴ or a monoallelic mutation in *PROKR2* (see above).

Genotype–phenotype correlation

For each genetic form of KS identified so far, the clinical heterogeneity of the disease within affected families clearly indicates that the manifestation of KS phenotypes is dependent on factors other than the mutated gene itself. These factors probably include epigenetic factors and modifier genes, both of which have not yet been identified. In addition, digenic or oligogenic inheritance presumably accounts in part for the long recognised incomplete penetrance of the disease. That said, some general features have emerged from clinical observations in the patients affected by the different genetic forms of KS. For instance, a greater variability in the degree of hypogonadism has been observed in patients carrying mutations in *FGFR1*, *FGF8*, *PROKR2*, or *PROK2*, than in *KAL1* patients.^{7,10,65,70–72} In particular, spontaneously fertile individuals carrying mutations in any of the four autosomal KS genes account for the transmission of the disease over several generations, whereas the X-linked form of KS is usually transmitted by the female carriers of *KAL1* mutations, who are clinically unaffected. Among the variety of non-reproductive and non-olfactory disorders that affect a fraction of the KS patients, some have been reported for specific genetic forms of the disease. For instance, unilateral renal agenesis occurs in approximately 30% of *KAL1* patients,^{31,32} but has so far not been reported in patients with *FGFR1*, *FGF8*, *PROKR2*, or *PROK2* mutations. On the other hand, the loss of nasal cartilage, external ear hypoplasia, and skeletal anomalies of the hands or feet, have only been reported in *KAL2* patients.^{7,13,48} By contrast, hearing impairment is

Table 1 A clinical comparison between *KAL1* and *KAL2* genetic forms of Kallmann syndrome

Genetic form	<i>KAL1</i>	<i>KAL2</i>
Gene (location)	<i>KAL1</i> (Xp22.3)	<i>FGFR1</i> (8p12)
Mode of transmission	X chromosome-linked	Autosomal dominant (incomplete penetrance)
Smell deficiency	Hyposmia to anosmia	None to anosmia
Hypogonadism	Usually severe	Highly variable
<i>Non-reproductive and non-olfactory anomalies</i>		
Bimanual synkinesis	Yes (>75%)	Uncommon
Renal agenesis	Yes (30%)	Not reported
Cleft lip/palate	No, but high arched palate	Yes (25–30%)
Tooth agenesis	Yes	Yes (frequent?)
Hearing impairment	Yes (unknown frequency)	Yes (unknown frequency)
Other anomalies	Pes cavus, ptosis	Corpus callosum agenesis, external ear hypoplasia, absent nasal cartilage, hand/foot skeletal anomalies, iris coloboma

common to several genetic forms of KS,^{7,8,13,23,24,29,65} although it should be noted that the underlying defect (conductive, perceptive, or mixed) is likely to vary between different genetic forms. Palate defects should also be considered as one of these shared traits, even though the severity differs between *KAL1* (high arched palate) and *KAL2* (cleft palate). The cleft lip and/or palate may occur in as many as 25–30% of the *KAL2* cases.^{7,11–13,65,73} Lastly, bimanual synkinesis is highly prevalent in *KAL1* (maybe >75% of the cases),^{17,22} but seems to be much less common in *KAL2*.^{7,12} Table 1 displays a comparison between *KAL1* and *KAL2* clinical features. Additional anomalies have so far not been reported in KS patients carrying mutations in *PROKR2* or *PROK2*, with the notable exception of a severe sleep disorder and marked obesity in one patient,¹⁰ which could be related to the known function of prokineticin-2 signalling in behavioural circadian rhythms, including sleep–wake and ingestive behaviour.⁷⁴ The prevalence of sleeping and eating disorders in KS patients, however, remains to be determined.

Treatment of the hypogonadism

The treatment of hypogonadism in KS aims first to initiate virilisation or breast development, and second to develop fertility. Hormone replacement therapy, usually with testosterone for males and combined oestrogen and progesterone

for females, is the treatment to stimulate the development of secondary sexual characteristics. For those desiring fertility, either gonadotropins or pulsatile GnRH can be used to obtain testicular growth and sperm production in males or ovulation in females. Both treatments restore fertility in a vast majority of affected individuals.⁷⁵ It is still unknown whether transient hormone replacement therapy in affected male infants to simulate the postnatal surge in gonadotropins could have later impact on their sexual life and reproductive prognosis (see reference⁵⁸).

Pathophysiology

Most phenotypic anomalies reported in KS may result from the developmental failures during the organogenesis period, between 4 and 10 embryonic weeks (see reference⁷⁶ for review). The developmental disorder leading to the absence (or hypoplasia) of the olfactory bulbs and tracts, and to anosmia in KS is not completely understood. It may involve a failure of the terminal elongation or targeting of olfactory axons, a primary morphogenetic defect of the olfactory bulbs (at the end of the 6th embryonic week), and a later defect in axonal branching of the olfactory bulb output neurons. In the late 1980s, new light was shed on the mechanism of the GnRH deficiency underlying KS hypogonadism, with the discovery of a close topographic link between the peripheral olfactory system and neuroendocrine GnRH cells during the embryonic life. These cells undergo a migration, beginning in the 6th embryonic week, from the olfactory epithelium to the forebrain along the olfactory nerve pathway.⁷⁷ In a human fetus carrying a chromosomal deletion at Xp22.3 that included *KAL1*, it was shown that GnRH cells had not migrated normally and had accumulated in the upper nasal region.⁷⁸ There are presently no pathohistological data to verify that the embryonic migration of GnRH cells is arrested in individuals affected by other genetic forms of KS. In *Prokr2* or *Prokr2* homozygous knockout mice, and mice carrying *Fgfr1* or *Fgf8* hypomorphic mutations in the homozygous state, however, the migration of these cells is disrupted too.^{14,65,79,80} The mechanism of the putative defect of GnRH cell migration in KS is still conjectural. It could be either a consequence of the early degeneration of olfactory nerve and terminal nerve axons, which act as guiding cues, or a process directly affecting the GnRH cells themselves. Moreover, defects in GnRH cell fate specification, differentiation, axon elongation, or axon targeting to the hypothalamus median eminence may also contribute to the GnRH deficiency, at least in the *KAL2* genetic form of the disease (see reference^{35,80}).

Unresolved questions

Although KS was identified as a hereditary disease more than 60 years ago, its genetics is still incompletely under-

stood, including its much higher prevalence in males than in females. Among many unresolved genetic and clinical questions are the following:

1. What is the actual prevalence of KS, especially in females?
2. What is the KS phenotypic spectrum, especially with respect to non-reproductive non-olfactory additional disorders?
3. Is hereditary anosmia without apparent hypogonadism a clinical form of KS?
4. Where is the nosological frontier between KS and normosmic HH?
5. How many different disease genes are involved in KS, and how do they functionally interact in the development of olfactory and GnRH neuroendocrine systems (see reference⁸¹ for current hypotheses)?
6. What is the prevalence of the digenic/oligogenic mode of inheritance among KS patients? Indeed, answer to this question is a prerequisite to assess disease recurrence risk in the affected families.
7. Why is KS more frequent in males than in females?

Given that the X-linked recessive form does not account for the higher disease prevalence in males, could it be that females are to some extent protected against disease occurrence by physiologically higher levels of *KAL1* expression during the embryonic life compared to males (because *KAL1* partially escapes the X-chromosome inactivation process in humans⁶²)?

References

- 1 Maestre de San Juan A: Falta total de los nervios olfatorios con anosmia en un individuo en quien existía una atrofia congénita de los testículos y miembro viril. *Siglo Medico* 1856; **131**: 211.
- 2 Kallmann FJ, Schoenfeld WA, Barrera SE: The genetic aspects of primary eunuchoidism. *Am J Mental Deficiency* 1944; **XLVIII**: 203–236.
- 3 de Morsier G, Gauthier G: La dysplasie olfacto-génitale. *Pathol Biol* 1963; **11**: 1267–1272.
- 4 Naftolin F, Harris GW, Bobrow M: Effect of purified luteinizing hormone releasing factor on normal and hypogonadotropic anosmic men. *Nature* 1971; **232**: 496–497.
- 5 Santen RJ, Paulsen CA: Hypogonadotropic eunuchoidism. I. Clinical study of the mode of inheritance. *J Clin Endocrinol Metab* 1972; **36**: 47–54.
- 6 Lieblich JM, Rogol AD, White BJ, Rosen SW: Syndrome of anosmia with hypogonadotropic hypogonadism (Kallmann syndrome). *Am J Med* 1982; **73**: 506–519.
- 7 Dodé C, Levilliers J, Dupont J-M *et al*: Loss-of-function mutations in *FGFR1* cause autosomal dominant Kallmann syndrome. *Nat Genet* 2003; **33**: 463–465.
- 8 Massin N, Pêcheux C, Eloit C *et al*: X chromosome-linked Kallmann syndrome: clinical heterogeneity in three siblings carrying an intragenic deletion of the *KAL-1* gene. *J Clin Endocrinol Metab* 2003; **88**: 2003–2008.
- 9 Pitteloud N, Acierno J, Meysing A, Dwyer A, Hayes F, Crowley W: Reversible Kallmann syndrome, delayed puberty, and isolated anosmia occurring in a single family with a mutation in the *FGFR1* gene. *J Clin Endocrinol Metab* 2005; **90**: 1317–1322.

- 10 Dodé C, Teixeira L, Levilliers J *et al*: Kallmann syndrome: mutations in the genes encoding prokineticin-2 and prokineticin receptor-2. *PLoS Genetics* 2006; **2**: 1648–1652.
- 11 Pitteloud N, Acierno Jr JS, Meysing A *et al*: Mutations in fibroblast growth factor receptor 1 cause both Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism. *Proc Natl Acad Sci USA* 2006; **103**: 6281–6286.
- 12 Trarbach EB, Costa EM, Versiani B *et al*: Novel fibroblast growth factor receptor 1 mutations in patients with congenital hypogonadotropic hypogonadism with and without anosmia. *J Clin Endocrinol Metab* 2006; **91**: 4006–4012.
- 13 Dodé C, Fouveaut C, Mortier G *et al*: Novel *FGFR1* sequence variants in Kallmann syndrome, and genetic evidence that the *FGFR1c* isoform is required in olfactory bulb and palate morphogenesis. *Hum Mutat* 2007; **28**: 97–98.
- 14 Pitteloud N, Zhang C, Pignatelli D *et al*: Loss-of-function mutation in the prokineticin 2 gene causes Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism. *Proc Natl Acad Sci USA* 2007; **104**: 17447–17452.
- 15 Hermanussen M, Sippell WG: Heterogeneity of Kallmann's syndrome. *Clin Genet* 1985; **28**: 106–111.
- 16 Hipkin L, Casson I, Davis J: Identical twins discordant for Kallmann's syndrome. *J Med Genet* 1990; **27**: 198–199.
- 17 Quinton R, Duke VM, Robertson A *et al*: Idiopathic gonadotrophin deficiency: genetic questions addressed through phenotypic characterization. *Clin Endocrinol (Oxf)* 2001; **55**: 163–174.
- 18 Ribeiro RS, Vieira TC, Abucham J: Reversible Kallmann syndrome: report of the first case with a *KAL1* mutation and literature review. *Eur J Endocrinol* 2007; **156**: 285–290.
- 19 Raivio T, Falardeau J, Dwyer A *et al*: Reversal of idiopathic hypogonadotropic hypogonadism. *N Engl J Med* 2007; **357**: 863–873.
- 20 Conrad B, Kriebel J, Hetzel WD: Hereditary bimanual synkinesis combined with hypogonadotropic hypogonadism and anosmia in four brothers. *J Neurol* 1978; **218**: 263–274.
- 21 Schwankhaus JD, Currie J, Jaffe MJ, Rose SR, Sherins RJ: Neurologic findings in men with isolated hypogonadotropic hypogonadism. *Neurology* 1989; **39**: 223–226.
- 22 Quinton R, Duke VM, de Zoysa PA *et al*: The neuroradiology of Kallmann's syndrome: a genotypic and phenotypic analysis. *J Clin Endocrinol Metab* 1996; **81**: 3010–3017.
- 23 Söderlund D, Canto P, Méndez J: Identification of three novel mutations in the *KAL1* gene in patients with Kallmann syndrome. *J Clin Endocrinol Metab* 2002; **87**: 2589–2592.
- 24 Hardelin J-P, Levilliers J, Young J *et al*: Xp22.3 deletions in isolated familial Kallmann's syndrome. *J Clin Endocrinol Metab* 1993; **76**: 827–831.
- 25 Reardon W: Kallmann syndrome presenting as congenital ptosis in brothers. *Clin Dysmorphol* 2007; **16**: 207–208.
- 26 Kertzman C, Robinson DL, Sherins RJ, Schwankhaus JD, Mc Clurkin JW: Abnormalities in visual spatial attention in men with mirror movements associated with isolated hypogonadotropic hypogonadism. *Neurology* 1990; **40**: 1057–1063.
- 27 Hill J, Elliott C, Colquhoun I: Audiological, vestibular and radiological abnormalities in Kallmann's syndrome. *J Laryngol Otol* 1992; **106**: 530–534.
- 28 Coatesworth AP, Woodhead CJ: Conductive hearing loss associated with Kallmann's syndrome. *J Laryngol Otol* 2002; **116**: 125–126.
- 29 Sato N, Katsumata N, Kagami M *et al*: Clinical assessment and mutation analysis of Kallmann syndrome 1 (*KAL1*) and fibroblast growth factor receptor 1 (*FGFR1*, or *KAL2*) in five families and 18 sporadic patients. *J Clin Endocrinol Metab* 2004; **89**: 1079–1088.
- 30 Wegenke JD, Uehling DT, Wear Jr JB *et al*: Familial Kallmann syndrome with unilateral renal aplasia. *Clin Genet* 1975; **7**: 368–381.
- 31 Hardelin J-P, Levilliers J, Blanchard S *et al*: Heterogeneity in the mutations responsible for X chromosome-linked Kallmann syndrome. *Hum Mol Genet* 1993; **2**: 373–377.
- 32 Kirk J, Grant D, Besser G *et al*: Unilateral renal aplasia in X-linked Kallmann's syndrome. *Clin Genet* 1994; **46**: 260–262.
- 33 Molsted K, Kjaer I, Giwercman A, Versterhaug S, Skakkebaek N: Craniofacial morphology in patients with Kallmann's syndrome with and without cleft lip and palate. *Cleft Palate-Craniofacial J* 1997; **34**: 417–424.
- 34 de Zegher F, Lagae L, Declerck D, Vinckier F: Kallmann syndrome and delayed puberty associated with agenesis of lateral maxillary incisors. *J Craniofac Genet Dev Biol* 1995; **15**: 87–89.
- 35 Tsai P-S, Gill J: Mechanisms of disease: insights into X-linked and autosomal-dominant Kallmann syndrome. *Nat Clin Pract Endocrinol Metab* 2006; **2**: 160–171.
- 36 Ballabio A, Andria G: Deletions and translocations involving the distal short arm of the human X chromosome: review and hypotheses. *Hum Mol Genet* 1992; **1**: 221–227.
- 37 de Roux N, Young J, Misrahi M *et al*: A family with hypogonadotropic hypogonadism and mutations in the gonadotropin-releasing hormone receptor. *N Engl J Med* 1997; **337**: 1597–15602.
- 38 de Roux N, Genin E, Carel JC, Matsuda F, Chaussain JL, Milgrom E: Hypogonadotropic hypogonadism due to loss of function of the *KISS1*-derived peptide receptor *GPR54*. *Proc Natl Acad Sci USA* 2003; **100**: 10972–10976.
- 39 Seminara SB, Messenger S, Chatzidaki EE *et al*: The *GPR54* gene as a regulator of puberty. *N Engl J Med* 2003; **349**: 1614–1627.
- 40 Pitteloud N, Quinton R, Pearce S *et al*: Digenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonadism. *J Clin Invest* 2007; **117**: 457–463.
- 41 Sanlaville D, Verloes A: CHARGE syndrome: an update. *Eur J Hum Genet* 2007; **15**: 389–399.
- 42 Pinto G, Abadie V, Mesnage R *et al*: CHARGE syndrome includes hypogonadotropic hypogonadism and abnormal olfactory bulb development. *J Clin Endocrinol Metab* 2005; **90**: 5621–5626.
- 43 Blustajn J, Kirsch CF, Panigrahy A, Netchine I: Olfactory anomalies in CHARGE syndrome: imaging findings of a potential major diagnostic criterion. *AJNR Am J Neuroradiol* 2008; **29**: 1266–1269.
- 44 Cortez AB, Galindo A, Arensman FW, Van Dop C: Congenital heart disease associated with sporadic Kallmann syndrome. *Am J Med Genet* 1993; **46**: 551–554.
- 45 Klein VR, Friedman JM, Brookshire GS, Brown OE, Edman CD: Kallmann syndrome associated with choanal atresia. *Clin Genet* 1987; **31**: 224–227.
- 46 Ogata T, Fujiwara I, Ogawa E, Sato N, Udaka T, Kosaki K: Kallmann syndrome phenotype in a female patient with CHARGE syndrome and *CHD7* mutation. *Endocr J* 2006; **53**: 741–743.
- 47 Tellier AL, Cormier-Daire V, Abadie V *et al*: CHARGE syndrome: report of 47 cases and review. *Am J Med Genet* 1998; **76**: 402–409.
- 48 Zenaty D, Bretones P, Lambe C *et al*: Paediatric phenotype of Kallmann syndrome due to mutations of fibroblast growth factor receptor 1 (*FGFR1*). *Mol Cell Endocrinol* 2006; **254–255**: 78–83.
- 49 Vissers LE, van Ravenswaaij CM, Admiraal R *et al*: Mutations in a new member of the chromodomain gene family cause CHARGE syndrome. *Nat Genet* 2004; **36**: 955–957.
- 50 Lalani SR, Safiullah AM, Fernbach SD *et al*: Spectrum of *CHD7* mutations in 110 individuals with CHARGE syndrome and genotype-phenotype correlation. *Am J Hum Genet* 2006; **78**: 303–314.
- 51 Rosen S, Gann P, Rogol A: Congenital anosmia: detection thresholds for seven odorant classes in hypogonadal and eugonadal patients. *Ann Otol Rhinol Laryngol* 1979; **88**: 288.
- 52 Doty R, Shaman P, Dann M: Development of the University of Pennsylvania Smell identification Test, a standardized microencapsulated test of olfactory function. *Physiol Behav* 1984; **32**: 489–502.
- 53 Davidson TM, Murphy C: Rapid clinical evaluation of anosmia. The alcohol sniff test. *Arch Otolaryngol Head Neck Surg* 1997; **123**: 591–594.
- 54 Chalouhi C, Faulcon P, Le Bihan C, Hertz-Pannier L, Bonfils P, Abadie V: Olfactory evaluation in children: application to the CHARGE syndrome. *Pediatrics* 2005; **116**: e81–e88.

- 55 Klingmüller D, Duwes W, Krahe T, Brecht G, Schweikert H-U: Magnetic resonance imaging of the brain in patients with anosmia and hypothalamic hypogonadism (Kallmann's syndrome). *J Clin Endocrinol Metab* 1987; **65**: 581–584.
- 56 Whitcomb R, Crowley WJ: Male hypogonadotropic hypogonadism. *Endocrinol Metab Clin North Am* 1993; **22**: 125–143.
- 57 Seminara SB, Hayes FJ, Crowley Jr WF: Gonadotropin-releasing hormone deficiency in the human (idiopathic hypogonadotropic hypogonadism and Kallmann's syndrome): pathophysiological and genetic considerations. *Endocr Rev* 1998; **19**: 521–539.
- 58 Grumbach MM: A window of opportunity: the diagnosis of gonadotropin deficiency in the male infant. *J Clin Endocrinol Metab* 2005; **90**: 3122–3127.
- 59 Truwit CL, Barkovich AJ, Grumbach MM, Martini JJ: MR imaging of Kallmann syndrome, a genetic disorder of neuronal migration affecting the olfactory and genital systems. *AJNR Am J Neuroradiol* 1993; **14**: 827–838.
- 60 Birnbacher R, Wandl-Vergesslich K, Frisch H: Diagnosis of X-recessive Kallmann syndrome in early infancy. Evidence of hypoplastic rhinencephalon. *Eur J Pediatr* 1994; **153**: 245–247.
- 61 White BJ, Rogol AD, Brown KS, Lieblich JM, Rosen SW: The syndrome of anosmia with hypogonadotropic hypogonadism: a genetic study of 18 new families and a review. *Am J Med Genet* 1983; **15**: 417–435.
- 62 Franco B, Guioli S, Pragliola A *et al*: A gene deleted in Kallmann's syndrome shares homology with neural cell adhesion and axonal path-finding molecules. *Nature* 1991; **353**: 529–536.
- 63 Legouis R, Hardelin J-P, Levilliers J *et al*: The candidate gene for the X-linked Kallmann syndrome encodes a protein related to adhesion molecules. *Cell* 1991; **67**: 423–435.
- 64 Hardelin J-P, Levilliers J, del Castillo I *et al*: X chromosome-linked Kallmann syndrome: stop mutations validate the candidate gene. *Proc Natl Acad Sci USA* 1992; **89**: 8190–8194.
- 65 Falardeau J, Chung WC, Beenken A *et al*: Decreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in humans and mice. *J Clin Invest* 2008; **118**: 2822–2831.
- 66 Sato N, Ohyama K, Fukami M, Okada M, Ogata T: Kallmann syndrome: somatic and germline mutations of the fibroblast growth factor receptor 1 gene in a mother and the son. *J Clin Endocrinol Metab* 2006; **91**: 1415–1418.
- 67 Cole LW, Sidis Y, Zhang C *et al*: Mutations in prokineticin 2 (PROK2) and PROK2 receptor 2 (PROKR2) in human gonadotropin-releasing hormone deficiency: molecular genetics and clinical spectrum. *J Clin Endocrinol Metab* 2008; **93**: 3551–3559.
- 68 Monnier C, Dodé C, Fabre L *et al*: *PROKR2* missense mutations associated with Kallmann syndrome impair receptor signalling-activity. *Hum Mol Genet* 2008 [Epub ahead of print]. PMID 18826963.
- 69 Leroy C, Fouveaut C, Leclercq S *et al*: Biallelic mutations in the prokineticin-2 gene in two sporadic cases of Kallmann syndrome. *Eur J Hum Genet* 2008; **16**: 865–868.
- 70 Oliveira LM, Seminara SB, Beranova M *et al*: The importance of autosomal genes in Kallmann syndrome: genotype-phenotype correlations and neuroendocrine characteristics. *J Clin Endocrinol Metab* 2001; **86**: 1532–1538.
- 71 Pitteloud N, Meysing A, Quinton R *et al*: Mutations in fibroblast growth factor receptor 1 cause Kallmann syndrome with a wide spectrum of reproductive phenotypes. *Mol Cell Endocrinol* 2006; **254–255**: 60–69.
- 72 Salenave S, Chanson P, Bry H *et al*: Kallmann's syndrome: a comparison of the reproductive phenotypes in men carrying *KAL1* and *FGFR1/KAL2* mutations. *J Clin Endocrinol Metab* 2008; **93**: 758–763.
- 73 Albuisson J, Pêcheux C, Carel J-C *et al*: Kallmann syndrome: 14 novel mutations in *KAL1* and *FGFR1 (KAL2)*. *Hum Mutat* 2005; **25**: 98–99.
- 74 Zhou QY, Cheng MY: Prokineticin 2 and circadian clock output. *FEBS J* 2005; **272**: 5703–5709.
- 75 Buchter D, Behre HM, Kliesch S, Nieschlag E: Pulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 cases. *Eur J Endocrinol* 1998; **139**: 298–303.
- 76 Hardelin J-P, Dodé C: *KAL1*, *FGFR1*, *PROKR2*, *PROK2*, and Kallmann syndrome; in: Epstein C, Erickson R, Wynshaw-Boris A (eds): *Inborn errors of development*. New York: Oxford University Press, 2008, chapter 47, pp 482–490.
- 77 Schwanzel-Fukuda M, Crossin KL, Pfaff DW, Bouloux PMG, Hardelin J-P, Petit C: Migration of luteinizing hormone-releasing hormone (LHRH) neurons in early human embryos. *J Comp Neurol* 1996; **366**: 547–557.
- 78 Schwanzel-Fukuda M, Bick D, Pfaff DW: Luteinizing hormone-releasing hormone (LHRH)-expressing cells do not migrate normally in an inherited hypogonadal (Kallmann) syndrome. *Mol Brain Res* 1989; **6**: 311–326.
- 79 Matsumoto S, Yamazaki C, Masumoto KH *et al*: Abnormal development of the olfactory bulb and reproductive system in mice lacking prokineticin receptor PKR2. *Proc Natl Acad Sci USA* 2006; **103**: 4140–4145.
- 80 Chung WC, Moyle SS, Tsai PS: Fibroblast growth factor 8 signaling through Fgf receptor 1 is required for the emergence of gonadotropin-releasing hormone neurons. *Endocrinology* 2008; **149**: 4997–5003.
- 81 Hardelin J-P, Dodé C: The complex genetics of Kallmann syndrome: *KAL1*, *FGFR1*, *FGF8*, *PROKR2*, *PROK2*, *et al*. *Sex Dev* 2008; **2**: 181–193.

Supplementary Information accompanies the paper on European Journal of Human Genetics website (<http://www.nature.com/ejhg>)